A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
16 Feb 2022 Results of a pooled analysis from a subset of participants from A5336 and A5337 assessed if these immune-modulators affect CMV DNA to elucidate a possible contributing effect of CMV replication on inflammatory outcomes presented at the 29th Conference on Retroviruses and Opportunistic Infections
24 Jun 2021 Results (n=39)evaluating pharmacokinetics of Ruxolitinib in HIV suppressed patients on Antiretroviral Agents Therapy(efavirenz), published in the Journal of Clinical Pharmacology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com